

13 November 2023

## Freedom of Information Act request, technology transfer, IMPFOI-23-600, FOI request and Imperial College response

*Q1. Can you release your internal strategy, policy, or any kind of public statement regarding the technology transfer (e.g. licensing, patenting) of COVID-19 related health technologies? Has anything changed since September 2022 when we sent the last request?*

No, strategies for licencing and patenting of COVID-19 related health technologies are specific to each technology.

*Q2. Does the institution have a formal policy on licensing and patenting of health technologies? If yes, please provide a link or PDF to the relevant policy document. Has anything changed since October 2022 when we sent the last request?*

No. Licensing and patenting of COVID-19 related technologies is in line with College's usual business practices.

*Q3. Has the university updated their strategy regarding the licensing and patenting of health technologies since October 2022 when we sent the last request?*

No. Updates to licensing and patenting strategies at College regularly occur as part of continuous improvement initiatives.

*Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses (time period: October 2022-October 2023). Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)*

Number of Licences	Technology	Country of Licensing	Exclusive, Non-Exclusive
1	Method and apparatus	World Wide (WW)	Exclusive
1	Gene transfer	World Wide (WW)	Non-Exclusive
1	Ventilators	World Wide (WW)	Exclusive

*Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted (time period: October 2022-October 2023). If you use abbreviations in this list, please clarify the abbreviations.*

Please see table below for details of patents filed.

Patent Family	IP Asset Name	Patent Country	Patent Stage	Granted
1	Vaccine	AU, ZA, AE, BR, KR, CN, JP, US, EP, CA, IN	National Phase	
1	Method and apparatus	AU, NZ, ZA, EP, CN, IL, TH, BR, AE, MY, CA, MX, RU, IN, JP, KR, US	National Phase	
1	Ventilator	US, ID, IN, EP, CN	National Phase	
1	Method and apparatus	US, CN, IN, EP	National Phase	
1	Method and apparatus	US, CN, IN, EP	National Phase	
1	Method and apparatus	US, CN, IN, EP	National Phase	
1	Method and apparatus	US, CN, IN, EP	National Phase/Granted	CH, FR, DE, UK
1	Method and apparatus	US, EP	National Phase	
1	Method and apparatus	US, EP, UK	National Phase	
1	Amplification methods	PCT	PCT	
1	A method for determining diagnostic outcome	US, EP	National Phase	
1	Detection of pathogens	US	National Phase	
1	Gene transfer	PCT	PCT	
1	pathogen detection assay	PCT	PCT	

*Q6. Does the institution have any plans on signing up to the Open-COVID pledge (<https://opencovidpledge.org/>) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with Open-COVID pledge, please provide files related to these meetings if they took place since October 2022.*

Imperial College has no records of discussions on this.

*Q7. Has the institution considered the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with either C-TAP and/or MPP please provide files related to these meetings if they took place since October 2022.*

Imperial College has no records of discussions on this.

*Q8. Has the institution signed on to the AUTM COVID-19 Licensing Guidelines (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with AUTM on these guidelines please provide files related to these meetings if they took place since October 2022.*

Imperial College has no records of discussions on this.

*Q9. Has the institution engaged with the WHO technology transfer hub during the pandemic (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with the WHO technology transfer hub please provide files related to these meetings if they took place since October 2022.*

Imperial College has no records of discussions on this.

*Q10. Has the institution shared their best practices on the technology transfer of COVID-19 health technologies with other institutions (since January 2020)? If yes, please specify. If the university has engaged in specific discussions with other universities on COVID-19 health technologies in the context of technology transfer, please provide files related to these meetings if they took place since October 2022.*

Imperial College has no records of discussions on this.

*Q11. Are there any other steps the university has taken between January 2020 and October 2023 to promote the accessibility, affordability, or availability of COVID-19 health technologies beyond the questions listed here?*

Licence agreements with spinouts active in Covid-19 diagnostics area ensured tiered royalty terms for developed vs LMIC territories to enable access.